ProCE Banner Activity

Alectinib: A New Standard of Care for Newly Diagnosed Advanced ALK-Positive NSCLC

Clinical Thought
New data from ASCO 2017 has established alectinib as a new standard of care for newly diagnosed ALK-positive NSCLC. Alice Shaw, MD, PhD, discusses the latest clinical data from the ALEX trial supporting this landmark change in advanced NSCLC management.

Released: July 07, 2017

Expiration: July 06, 2018

No longer available for credit.

Share

Faculty

Alice Shaw

Alice Shaw, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Director, Center for Thoracic Centers
Paula OKeefe Endowed Chair in Thoracic Oncology
MGH Cancer Center/Center for Thoracic Cancers
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Celgene

Genentech Roche Virology

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Alice Shaw, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Director, Center for Thoracic Centers
Paula OKeefe Endowed Chair in Thoracic Oncology
MGH Cancer Center/Center for Thoracic Cancers
Massachusetts General Hospital
Boston, Massachusetts

Alice Shaw, MD, PhD, has disclosed that she has received consulting fees from ARIAD, Blueprint Medicines, Daiichi Sankyo, EMD Serono, Genentech, Ignyta, Loxo Oncology, Novartis, Pfizer, Roche, and Taiho Oncology.